Adam Hutchings

GlaxoSmithKline

Stockley Park West

Uxbridge, Middlesex UB11 1BT

United Kingdom

Learn more about SSRN Profiles

SCHOLARLY PAPERS

1

DOWNLOADS

0

TOTAL CITATIONS

0

Feedback

Scholarly Papers (1)

Sort by:

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

1.

An Exploration of Incremental Net Health Benefit Analysis: A Quantitative Assessment of the Benefit-Harm Profile of Natalizumab in Relapsing Remitting Multiple Sclerosis

iHEA 2007 6th World Congress: Explorations in Health Economics Paper

Posted: 20 Jun 2007

Kate Lovibond, Adam Hutchings and Martin O'Leary

City University, London, GlaxoSmithKline and GlaxoSmithKline

Abstract:

Feedback

All content on this site: Copyright © 2026 Elsevier Inc., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

We use cookies to help provide and enhance our service and tailor content.

To learn more, visit .